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Abstract
Background: A wide range of techniques is now available for analyzing regulatory networks. Nonetheless, most of
these techniques fail to interpret large-scale transcriptional data at the post-translational level.
Results: We address the question of using large-scale transcriptomic observation of a system perturbation to
analyze a regulatory network which contained several types of interactions - transcriptional and post-translational.
Our method consisted of post-processing the outputs of an open-source tool named BioQuali - an automatic
constraint-based analysis mimicking biologist’s local reasoning on a large scale. The post-processing relied on
differences in the behavior of the transcriptional and post-translational levels in the network. As a case study, we
analyzed a network representation of the genes and proteins controlled by an oncogene in the context of Ewing’s
sarcoma. The analysis allowed us to pinpoint active interactions specific to this cancer. We also identified the parts
of the network which were incomplete and should be submitted for further investigation.
Conclusions: The proposed approach is effective for the qualitative analysis of cancer networks. It allows the
integrative use of experimental data of various types in order to identify the specific information that should be
considered a priority in the initial - and possibly very large - experimental dataset. Iteratively, new dataset can be
introduced into the analysis to improve the network representation and make it more specific.
Background
Network modeling and data analysis in Cancer Systems
Biology
During the last decade, interest in using network models
for elucidating mechanisms of disease has constantly
increased [1]. In particular, identifying the pathways that
are responsible for malignancy is an important challenge
in Cancer Systems Biology [2,3]. Although it is now
accepted that cancer is a genetic disease, the levels of
gene expression remain, for many reasons, unreliable
indicators of causation [4]. First, the genetic perturba-
tions produce a multitude of changes, not all related to
the phenotype. Second, the mutated genes initiating the
processes are not detectable as differentially expressed.
Last but not least, important modifications of the path-
ways result from post-translational interactions that are
independent of the changes at the mRNA level.
Information on protein-protein and protein-DNA
interactions has recently become available for human
interaction pathways. Many groups combine literature
information and machine learning to build network
models for disease. It has been proposed that networks
can be used as filters to identify genes implicated in
cancer. For instance, Chuang and colleagues used net-
work models to improve markers for tumor classifica-
tions [3]. They identified mutated genes in cancer from
their effect on connected sub-networks of differentially
expressed genes. The sub-networks are proposed as
classifiers of tumors and could also serve to generate
new hypotheses about the disease. A similar idea has
been investigated by Ergun and colleagues [2]. They
identified groups of genes whose expressions are most
affected by disease. In order to find these genes, the
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dynamics of the network is modeled by simplified differ-
ential equations. The disease is supposed to affect tran-
scription rates by multiplying them by a gene-dependent
factor. Estimating this factor from data allows one to
rank genes according to a z-score representing the influ-
ence of the disease. Another method for determining
the genes most affected by disease has been applied to
cancer by Mani and colleagues [5]. Mutual information
(MI) quantifies the degree of dependence between inter-
acting genes. By computing the change of MI induced
by various tumor phenotypes in cohorts of patients, one
can assign to each tumor phenotype a set of genes that
are most affected. Various network-based classifiers of
tumors have been proposed elsewhere [6,7].
Constraint-based approaches for hypothesis generation
All approaches mentioned above face difficulties in the
quality of the network representation. Indeed, in any
network-based study of disease, the first step is the net-
work construction. “Gold standard” evidence from
curated databases and from the literature allow integrat-
ing a large amount of experimental and computational
evidence. Such evidence is gathered in a model, often
represented by an interaction graph that is prone to
incompleteness and uncertainty. Mutual information [5]
or other machine-learning methods [2,3] can be used to
fill in gaps in the network or, alternatively, to discard
interactions if their presence is not supported by data.
Nonetheless, the logical implications of the confronta-
tion between network models and data are insufficiently
explored by these methods.
A different class of approaches, less developed in can-
cer studies, uses model-checking and constraint-based
analysis to test and exploit the logical consistency
between model and data. Several types of queries can be
performed. They can be dynamic, although using differ-
ent temporal logics, like those implemented in the Bioc-
ham [8], BioNetGen [9] or GeneNetAnalyser [10]
softwares. Queries may also be static, particularly in the
case of middle and large-scale networks. For instance,
Bowers and colleagues rely on static logic relationships
to investigate protein network organization [11]. Baum-
bach and colleagues also used static rules to perform
predictions on corynebacterial regulatory networks [12].
We have recently designed a tool for constraint-based
analysis of interaction networks [13] named BioQuali
which aims at automatizing such approaches. The tool
solves large systems of qualitative equations which con-
nect the variations of a node to the variations of its pre-
cursors in the interaction graph. Applied to network
models, BioQuali can validate the existence of interac-
tions in a network and predict the variations of nodes
that are not directly measured. In case of conflict
between model and data, the origin of the conflict is
localized by analyzing the propagation of the constraints.
Then, new experiments can be suggested to check the
new hypotheses [14]. In this context, constraint-based
analysis complements statistical approaches in hypoth-
esis generation.
Alternative network representation coping with realistic
interactions and data
The main difficulty faced when applying such formal
methods lies in the network representation. Indeed,
most of models studied in this context are built from
curated databases or the literature. According to the
level of detail in the knowledge and the size of networks
at hand, most models do not discriminate between
mRNA and protein levels. The variables (node attri-
butes) are mRNA levels observed with microarrays.
However, protein levels are not always correlated to
mRNA levels, especially in cancer systems. In such
situations, it is vital to distinguish between transcrip-
tional, post-transcriptional and post-translational inter-
actions. Furthermore, new types of nodes should be
used whose attributes, though constrained by the net-
work, are not available in the experiment. Predicting the
attributes of these nodes (for instance, protein activities)
is essential for assessing the effectiveness of the
interactions.
In this paper we propose a constraint-based analysis of
a cancer network model. Our main concern is to iden-
tify and account first for uncorrelated protein and
mRNA levels, second for post-translational interactions.
We automatically modify the network representation so
that each gene satisfying our given criteria is represented
by two nodes, an mRNA and a protein node. Using the
BioQuali tool, we check consistency between the data
and two descriptions of the system: the initial network
built from a curated database and the modified network
with distinct interaction levels. We investigate the
results of the constraint-based analysis tool to predict
protein activities and identify active regulations in the
network. Within this framework, the notion of activity is
understood as interactions in the network that are logi-
cally required to obtain a given set of observations.
Lastly, we confront the results of our analysis to new
data in order to refine the model.
Other network representation studies, such as those
performed by Mani and colleagues [5], have suggested
distinctions between types of proteins - transcription
factors, non-TF and modulators according to their func-
tion in the cell. However, the representation of network
interactions and their relation to data is not equivalent
to ours. The network model in our constraint-based
approach is a signed interaction graph. The information
on the sign of interactions (inhibition, activation) is
essential for our analysis. MI-based networks use
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oriented interactions for which the sign information is
not important. More importantly, in these models post-
translational modifications are represented as modula-
tions of the interactions between transcription factors
and their targets. Our decision to separate protein and
mRNA nodes allows a more rigorous analysis of the
constraints. It can exploit data of both mRNA and pro-
tein types, and therefore performs hypothesis generation.
Analysis of a cancer network
To test our method, we used it to study Ewing’s sar-
coma. Ewing’s sarcoma is the second most common
malignant bone tumor in children and young adults.
Delattre and colleagues showed that it is associated in
more than 80% of cases with the t(11;22)(q24;q12) chro-
mosomal translocation [15,16]. The latter induces the
expression of the chimeric protein composed of the N
terminal part of the EWS gene with the ETS family
member FLI1 c-terminal part [17]. Consequently, EWS-
FLI acts as an aberrant transcriptional activator/repres-
sor in Ewing’s sarcoma by altering the expression of
specific target genes [18,19]. Our decision to analyze
Ewing’s sarcoma is motivated by two aspects. First, the
key genetic perturbation of the Ewing network is known
to be EWS-FLI1, a transcription factor present in the
majority of Ewing’s tumors [20]. Second, large datasets
accumulated on this cancer are available, making it of
particular interest for our approach. In cell lines, the
changes of genetic program induced by siRNA inhibi-
tion of the oncogene lead to cell cycle arrest in G0/G1.
Upon reactivation, most of the expression levels change
and the phenotypes are reversed. Altogether, this pro-
vides quite reliable datasets for the study of the network
perturbation. However, the precise regulatory pathways
of the EWS-FLI1 oncogene are not yet fully elucidated.
Identifying gene interactions that are potentially
involved in the regulation of EWS-FLI1-related path-
ways are of great interest for studying Ewing’s sarcoma.
Methods
Gene expression data, Ews-Fli1 regulatory network
Data on gene expression upon Ews-Fli1 knock down/rescue
in Ewing’s cancer cells
Transcriptome time-series data were obtained using
Affymetrix U133A microarray as published in [21]. In
this paper, Ewing cells were profiled upon EWS-FLI1
knocked down (with retroviral-mediated RNAi EF-2-
RNAi construct) and then rescued based on a tetracy-
cline-inducible EWS-FLI1 cDNA. Predicted variations of
gene expression during inhibition of EWS-FLI1 were
validated with additional experiments as follows. For
RT-QPCR and Western blotting experiments, EWS-FLI1
transcript was silenced and reactivated using a tetracy-
cline inducible shEWS-FLI1 specific construct in clones
derived from the A673 cell lines. Levels of IGF2 mRNA
(taqman Hs01005963_m1, Applied biosystems) and
FASLG mRNA (forward primer: ggaaagtggcccatttaaca
reverse primer: ccagaaagcaggacaattcc) were measured by
real-time quantitative polymerase-chain reaction (RT-
QPCR, normalized to RPLP0). Western blotting was
performed with IGF2 (AB9574, Abcam) and FASLG
(AB15285, Abcam) antibodies.
Regulatory network of EWS-FLI1 chimeric oncogene
An annotated gene regulatory and signaling model was
designed by our colleagues from Institut Curie [22]. The
model involves 130 genes selected according to the
strength of their response on the inhibition/reactivation
of EWS-FLI1. Using information from BIOBASE [23]
and manual curation of the literature, around 300 inter-
actions were selected to describe signaling pathways that
regulate key functions involved in tumor progression
(cell cycle phase transitions, apoptosis and cell migra-
tion). Products in the networks correspond to genes,
proteins, phosphorylated proteins - such as RB1_pho-
sphorylated - and protein complexes such as the com-
plex made of CCNB1 and CDK2. Due to lack of precise
knowledge, additional nodes were added to describe the
effects of families of proteins - such as the RAC family
which includes RAC1, RAC2 and RAC3. Interactions
issued or targeting such a node gather all interactions
known for at least one element in the family. Finally,
the network included some nodes to describe the phe-
notypic effects of the oncogene - apoptosis, cell migra-
tion, cell cycle anaphase, -G2, -M and -S phases.
From this annotation of the network we have
extracted an interaction graph as follows. Nodes of the
graph are given by the products that appear in the initial
model. Every interaction in the initial annotated model
is mapped to a labeled edge of the interaction graph.
Every edge represents a positive (‘+’ meaning up-regula-
tion), negative (‘-’, down-regulation) or dual (‘?’, the
actual regulation is unknown) influence of a source
node (precursor) on a target node (successor) (see Addi-
tional file 1: Interaction graph adapted from the original
network). Each interaction is also annotated with respect
to the type of interaction (transcriptional or post-trans-
lational, not shown). The interaction graph was further
modified according to the method proposed below to
enhance transcriptional and post-translational effects
(see the forthcoming section “First add-on: changing the
descriptive level of the network” and Additional File 2:
Modified interaction graph).
Extracting average trend of gene response to the oncogene
inhibition
We used a dedicated gene-level summarization and data
filtering process to analyze the Affymetrix data pub-
lished in [21]. Our goal was to capture the average
trend of the response of the network nodes to oncogene
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inhibition, that is, to identify nodes which are either cor-
related or anti-correlated to the oncogene inhibition
expression pattern. A pre-normalization procedure was
performed in [21]: (A) Checking for mis-targeted and
non-specific hybridization; (B) Background subtraction,
in order to remove the fluorescence induced by factors
other than hybridization of RNA to the chip. (C) Nor-
malizing the data using a Robust Multiarray Average
(RMA) method to remove systematic bias such as plat-
form-specific variations or the influence of non-biologi-
cal factors.
Starting from these data, a gene-level summarization
was performed by grouping the probe sets correspond-
ing to the same gene. Within such groups, all probe set
lines were kept instead of substituting them with the
single mean or median value. This allowed capturing
the statistical significance of the gene response including
all its transcript variances. Such gene groups of the full
microarray were then filtered to select only those genes
relevant for the network. An outlier removal procedure
was applied to the selected gene-level grouped data.
Data points were considered as outliers if their residuals
were larger than two standard deviations (SD) of the
gene dataset. The residuals were computed as the dis-
tance from the regression line built for each gene to
each of the gene set data points.
Finally, genes were arranged according to the signifi-
cance of their responses to the oncogene inhibition in
the Affymetrix microarrays [21]. To that end, the
response curves of the transcripts corresponding to a
gene were approximated with a linear function using lin-
ear regression. A gene was considered as significantly
responding to the oncogene inhibition if the regression
line fitted its response curves with a statistical signifi-
cance level of less than 5% and if the slope of the regres-
sion line significantly differed from zero. The latter
condition was checked indirectly using a two-sample
location test (Student’s t-test), which was performed on
the initial and final points of the time series. The signifi-
cance threshold was again fixed at 5%. Gene variation
signs were provided either by signs of slopes (for linear
regression) or by signs of variations (for Student’s t-test),
given that both parameters are statistically significant (p-
value less than 5%). A final adjustment to multiple pair-
wise tests - Holm-Bonferroni method, family-wise error
rate, false discovery rate - was not considered as relevant
since the list of genes had been previously reduced to a
much smaller one, corresponding to the studied network.
Constraint-based analysis: automatic reasoning tool and
its add-ons
BioQuali tool
We used an open-source software tool named BioQuali
to perform the qualitative analysis of EWS-FLI1
regulatory network [13]. BioQuali assesses the compat-
ibility between the network topology and the expression
variations induced by a disturbance of a system. It per-
forms automatic reasoning by propagating observations
along the network - as usually done when reasoning
about regulations - and checking whether this propaga-
tion either yields a contradiction or generates new
deductions. The tool is publicly available at http://geno-
web1.irisa.fr/Serveur-GPO/outils/interactionNetwork/
BIOQUALI/ [13].
The propagation of information is modeled by estab-
lishing a set of rules connecting the sign of a node var-
iation to the signs of its precursors’ variations in the
network. The main rule used in this paper was as fol-
lows: “the sign of a variation of a node cannot be oppo-
site to the sign of variations of all the influences it
gathers from its precursors in the network”. This rule
was mathematically proven to be valid if the initial and
the final states of the network are steady states of the
systems [24]. Note however that stronger rules may be
used when precise knowledge on interaction is available
[14]. The full set of rules is encoded as a system of qua-
litative constraints over its inputs (interaction graph and
observations on node variations). It may therefore be
considered as a constraint-based modeling tool. Solving
such a system is computationally difficult. The BioQuali
tool uses a dedicated constraints solver based on a deci-
sion diagram to overcome the computational difficulty
and solve systems of biological constraints in a reason-
able time. More details may be found in the software
publication [13,25].
The complete system of rules is analyzed to decide
whether the interaction graph is compatible with the
input data. Consistency means first that all the interac-
tions in the graph are in logical agreement with each
other and, second, that they do not conflict with experi-
mental observations. In case of disagreement, BioQuali
points out the inconsistent parts of the interaction
graph. In case of consistency, BioQuali generates a set
of predictions. They correspond to variations of non-
observed nodes that can be deduced from the observed
variations - that is, available data - by applying the gen-
eric biological rule introduced earlier. In Figure 1, we
detail a deduction process leading to such predictions.
Notice however that the BioQuali tool does not expli-
citly compute all the steps in this process: the software
encodes the steps into equations and then solves the
resulting system with efficient methods [25].
Two other examples of predictions are shown in Fig-
ure 2. They may be classified into two types with respect
to the constraint propagation as follows:
• Forward predictions are those which are straight-
forwardly deduced from precursors of a predicted
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node. Such predictions reflect the consequence of
the concerted action of the precursors on a pre-
dicted node in the network. If the actions of all the
precursors are known to have the same sign, the
node will potentially vary in the direction that is
imposed by this concerted action of its precursors.
• Backward predictions are deduced from the succes-
sors of a predicted node. These predictions represent
the only possible explanations of the associated
experimental observations and (or) the topology of
the network model. In contrast to forward ones,
backward predictions do not reflect the smooth pro-
pagation of an interaction along the network. They
may rather be seen as the result of an automatic glo-
bal reasoning to fill in gaps between observations on
node variations, in order to find the only possible
reasons for such observations.
Sorting predictions according to their significance can
be performed in different ways. A statistical significance
may be computed by pointing out those predictions that
are very specific to the dataset - slightly changed dataset
will no more generate a prediction. This approach was
used in [14] to test the robustness of a network and the
validity of reasoning rules. An alternative is to consider
all the predictions if they are not too numerous. As we
will detail in the sequel, we will consider all predictions
and favor those providing information on post-transla-
tional processes.
First add-on: changing the descriptive level of the network
The initial network represents a summary of our biolo-
gical knowledge about the pathways putatively influ-
enced by the oncogene. The nodes of this network
represent proteins, family of proteins, protein com-
plexes, and phenotypes. We have modified the network
in order to obtain an interaction graph, i.e. an oriented
signed graph whose arrows (directed edges) represent
interactions. An arrow connects two nodes if the tail
node influences the production of the head node. We
used the following criteria to modify the node represen-
tation of the initial network according to the transcrip-
tional or post-translational nature of interactions. This
Figure 1 BioQuali reasoning: logical steps leading to predictions. The tool encodes knowledge and observations into a system of
qualitative equations which is solved with an efficient algorithm [25]. The algorithm generates the complete set of solutions of these equations
and identifies invariants of the set of solutions, that is, node values that are constant throughout the entire set of solutions. These invariants are
called predictions. They can also result from the logical deduction process detailed above. The tool computes predictions without detailing the
reasoning steps, which would be impossible for large scale systems. Step 1 (backward deduction). The node mRNA AKT1 is observed as up-
regulated. It is regulated by IGF1 only. Therefore IGF1 should be up-regulated to explain the observation. Step 2 (backward deduction). IGF1
increase cannot be derived from an increase of its transcriptional activity since its mRNA is down-regulated. The only possible explanation is a
decrease of its inhibitor IGFBP3. Step 3 (backward deduction). Consequently, the only regulator of IGFBP3 should be up-regulated. Step 4
(forward deduction). All incoming regulations on PIK3C tend to increase it. This should result in an increase of the node activity. Final step. No
additional input or former deduction propagates. Deductions are all in agreement with each other. They are denoted as predictions and the
process ends. Alternatively, if a decrease of PIK3C is observed or deduced, the full process would fail, all deductions would be discarded and an
inconsistency diagnosis would be generated.
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allowed us to point out predictions which are relevant
from the post-translational viewpoint.
• Whenever possible, families of proteins are split
into representatives.
• For each protein which is a target of at least one
transcriptional regulation or which is coded by a
gene observed at the transcriptional level, the modi-
fied network will contain two nodes: the mRNA and
the protein. Alternative splicing can be taken into
account at this level, because several proteins can be
coded by the same gene and thus emerge from the
same mRNA.
• The mRNA nodes are targets of all transcriptional
regulations and up-regulate protein nodes - see Fig-
ure 2 for details. The underlying assumption here is
that increasing (or decreasing) the production of an
mRNA tends to increase (or decrease) the produc-
tion of the corresponding protein.
• The other protein nodes (not targets of post-trans-
lational interactions or whose mRNA are not
observed) remain as such (do not generate an
mRNA node).
• In the interaction graph, the precursors of protein
complexes are the constituent proteins.
• All protein-protein interactions are designated as
post-translational.
Second add-on: post-processing of BioQuali results and
classification of predictions
The post-processing of BioQuali predictions was
designed to enhance information on the activity of post-
translational interactions. We pointed out those predic-
tions which contradict the naive dogma of a correlation
between mRNA and protein levels.
• Type I. Predicted protein variations opposing
mRNA variations. Assuming that the variation of a
protein is correlated to the variation of its mRNA
unless it is perturbed by a post-translation process, a
prediction of Type I suggests that a post-transcrip-
tional regulation in the network strongly reverses
the transcriptional production of the predicted
Figure 2 Types of inconsistencies caused by undifferentiated mRNA and proteins in the network representation. On both images A and
C, inconsistencies occur on the node ‘B’. The first example (A) is inconsistent because the product of gene expression, represented by node ‘B’ is
a target of both transcriptional (TR) and post-translational (P-TR) regulations, which is not possible since transcriptional interactions should target
mRNAs, while post-translational interactions target proteins. This inconsistency is removed by the differentiation between mRNAs (node
‘mRNA_B’) and proteins (node ‘B’) as shown on image B. The second type of inconsistency (C) is caused by the association of experimental data
on variation in mRNA with a node which should represent a protein because it is a target of post-translational regulations. This inconsistency
can also be avoided if mRNAs and proteins are distinguished in the network (D).
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protein. Type I predictions are usually obtained as
backward deductions.
• Type II. Predicted protein variations with non-sig-
nificant mRNA variations. Predictions of this type
are similar to predictions of Type I and suggest the
existence of active post-translation interaction. How-
ever, the argument in favor of active interaction is
weaker here than for Type I predictions. Indeed, a
non-significant mRNA variation can be due to an
inaccuracy in the dataset - such as a lack of sensitiv-
ity of the microarray technique used to detect the
variation of the predicted gene.
• Type III. Predicted protein variations correlated to
mRNA variations. This type of predictions is fre-
quently derived from forward deductions, especially
when the observed mRNA is the only precursor of the
predicted protein. Such predictions simply suggest that
the transcriptional interactions are dominating.
This classification is obtained by performing a com-
plete comparison of predictions about mRNA and pro-
tein nodes. This functionality will be included in a
forthcoming distribution of BioQuali software.
Results and Discussion
Identification of significantly responsive genes
In the BioQuali setting, we call “observation” a gene
with significant variation. The set of observations used
for the qualitative analysis of the tumor oncogene net-
work was inferred from publicly available transcriptome
time series data from Smith and colleagues [21], see
Methods section. Time series provide the transient, that
is, intermediate values of the variables between the
initial and final states. Nonetheless, the BioQuali formal-
ism is not concerned with the details of the transients,
but only with the average trend of the response: increase
or decrease between the two states.
Such an average trend has a meaning also for variables
whose level in individual cells oscillates, as for instance
genes and proteins controlling the cell cycle. For these
variables, the average trend characterizes the change in
the population of cells (in our case the inhibition of the
oncogene induces a stop of proliferation in G1 and up-
regulates G1 specific genes). In both cases, a linear
regression method was applied (see Methods section) as
the simplest approximation which captures the average
trend of the response.
The analysis of the microarray time series data is sum-
marized in Table 1 and in Additional file 3: Results of
statistical analysis of microarray data [21]). It contains
33 genes of the network significantly responsive on
EWS-FLI1 inhibition.
This set of significant variations was complemented
with variations over non-transcriptional products,
including the variation of EWS-FLI1 protein and varia-
tions of ‘phenotypic’ nodes (representing apoptosis, cell
migration, cell cycle anaphase, -G2, -M and -S phases).
These variations were deduced from biological observa-
tions (see Additional file 4: Set of experimental
observations).
Consistency analysis of EWS-FLI1 regulatory network
We performed a consistency analysis of the EWS-FLI1 regu-
latory network two times: first in its original shape deduced
from BIOBASE and second time in its modified shape to
enhance post-translational processes. As an input dataset to
BioQuali we considered the observations resulting from the
inactivation of the oncogene performed by Smith and collea-
gues [21]. Since EWS-FLI1 is down-regulated during this
experiment, the variation of EWS-FLI1 was set to ‘-’.
According to the Identification of significantly responding
genes performed above, genes and proteins which are anti-
correlated to EWS-FLI1 and are up-regulated upon the
oncogene silencing have ‘+’ as a sign of variation, while cor-
related genes and proteins have ‘-’ as a sign of variation.
We first used the BioQuali tool to analyze the interac-
tion network directly inferred from EWS-FLI1 BIOBASE
regulatory network, prior to changing its descriptive
level: at this stage, mRNA and protein nodes were not
separated. The network was compared to the set of
observations resulting from transcriptome time series
data analysis. The analysis showed that this network
with non-distinguished gene products has two inconsis-
tent parts on nodes ‘(PIK3R.)’ and ‘Cell Migration’ (Fig-
ure 3). Both cases of inconsistency resulted from
experimental observations on their preceding nodes. For
both (PIK3R.) and Cell Migration nodes, the observed
variation cannot be deduced from variations in their
precursors (PDGFRB for (PIK3R.), see Figure 3A, and
(RAC.) and (RHO.) for Cell Migration, Figure 3B). This
suggests that the observed inconsistencies are due to
deficiency in the network topology representation: the
experimental observations were made at mRNA level
(microarray data), but they are associated with nodes
that represent proteins (interactions of the inconsistent
parts are post-translational). This supports our proposi-
tion of differentiation between transcriptional and post-
translational products in regulatory networks.
The original network was then modified by separating
mRNAs and proteins as described in the Method section
(Additional file 2: Modified interaction graph). BioQuali
analysis of the new enriched interaction network with
the observation dataset showed that the new network is
consistent with the experimental observations.
Predictions on the enriched network
The analysis of the enriched network using BioQuali
resulted in 31 predictions about variations
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corresponding to different node types, as follows: 4 pre-
dictions made about mRNAs, 17 predictions made
about proteins (with one protein representing a phos-
phorylated protein), 5 predictions made about nodes
representing protein complexes and 5 predictions made
about nodes representing protein groups/families (Table
2). All variations predicted by BioQuali - except those
about protein complex and phenotypic nodes - were
compared to experimental observations on the expres-
sion levels of their corresponding mRNAs, according to
the classification of predictions introduced in the
Method section. This classification identified eight pre-
dictions which allow us to discuss the existence of active
regulations. Five predictions are of Type II - CDC2,
IGF2, RB1-phosphorylated, TGFBR2 and TP73- and
three predictions are of Type I for proteins or families
-(RAC.), IGF1 and IGFBP3. The remaining 14 predic-
tions on proteins and protein groups/families are of
Type III.
From the 14 predictions of Type III, a path of predic-
tions was selected for experimental validation of the
approach. We considered FASLG as an important node
to be checked since the BioQuali logics applied to its
transcript variations both implies that the protein
FASLG is increasing and that JUN, the only precursor
to FASLG mRNA, is increasing as well - see Figure 4B
for details. Results of quantitative real-time PCR con-
firmed that FASLG mRNA anti-correlates with EWS-
FLI1 (Figure 5), inducing an increasing variation of the
transcript during the oncogene inhibition. Western blot
on FASLG protein (Figure 6) confirms the ‘forward’ pre-
diction ‘FASLG = ‘+”.
Type II predictions
Type II predictions are more informative than those of
Type III since they correspond to proteins which
mRNAs were not observed with a significant p-value
during the oncogene inhibition. This suggests that a
phenomenon occurs at the post-translational level which
is not initiated at the transcriptional level.
The prediction about the TGFBR2 protein is a direct
consequence of another prediction, about its mRNA.
Indeed, TGFBR2 mRNA is predicted as ‘+’ by a for-
ward prediction sourced in its inhibition by the inhib-
ited oncogene EWS-FLI1, its only precursor (Figure 4A
and Table 2). The production of TGFBR2 is regulated
by its transcript only, and is therefore activated as well.
Table 1 Significantly varying products upon EWS-FLI1 oncogene silencing
Node name Variation Node name Variation Node name Variation
mRNA_RAS + mRNA_ECM1 + mRNA_RBL2 -
mRNA_CCNE_ + mRNA_ECM2 + mRNA_SKP2 +
mRNA_NFKB_ + mRNA_FAS - mRNA_SOS2 +
mRNA_PIK3C_ + mRNA_FASLG + mRNA_TNFAIP3 +
mRNA_PIK3R_ - mRNA_IER3 + mRNA_TNFRSF1A +
mRNA_RAC_ + mRNA_IGF1 - Phenotypic_observations
mRNA_RHO_ + mRNA_IGFBP3 +
mRNA_TGFB_ + mRNA_JUN + EWS-FLI1 -
mRNA_TNF_ + mRNA_MAPK8 + Cell_Cycle_Anaphase -
mRNA_AKT1 + mRNA_MYC - Cell_Cycle_G2 -
mRNA_CDKN1A + mRNA_MYCBP - Cell_Cycle_M -
mRNA_CDKN1C + mRNA_PDGFRB + Cell_Cycle_S -
mRNA_CYCS - mRNA_PRKCB1 - Cell_Migration -
mRNA_E2F5 - mRNA_RASA1 + Apoptosis +
List of observations used as an input set for BioQuali. Table contains the list of significantly varying genes resulting from the analysis of microarray data [21]. The
last seven lines of the third column contain additional variations on so-called ‘phenotypical nodes’ and on the EWS-FLI1 protein. They summarize the current
literature-derived knowledge on cell behavior upon silencing EWS-FLI1 oncogene.
Figure 3 Inconsistencies in the original interaction graph. The
inconsistencies indicate parts of the network where the original
regulatory model fails to satisfy the generic biological rule of
BioQuali. In part A, node (PIK3R.) has only one precursor, PDGFRB,
and its variation (PDGFRB = ‘+’) cannot explain the variation of
(PIK3R.) ((PIK3R.) = ‘-’). In part B, the variation of the phenotypic
node ‘Cell Migration’ (’Cell Migration’ = ‘-’) cannot be explained by
either of the variations of its precursors: (RAC.) = ‘+’ and (RHO.) =
‘+’.
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This is in agreement with previously reported down-
regulation of TGFBR2 by EWS-FLI1 [26,21,27]. This
also points out a lack in sensitivity of the Affymetrix
data, which did not report a significant variation of
TGFBR2 mRNA.
Among the other Type II predictions, we would point
out the prediction about the protein TP73 as down-
regulated during the inhibition of EWS-FLI1. The
source of the prediction is the following: TP73 is the
only inhibitor of PDGFRB mRNA which is observed as
Table 2 Summary of EWS-FLI1 network analysis
Prediction Product Deduction
type
Functional
type
Source of the prediction
Protein nodes
(PIK3C.) = + Forward Type III obs. mRNA (PIK3C.), pred. (.RAS), pred.
IGF1
(.RAS) = + Backward Type III pred. IGFBP3, obs. mRNA IGFBP3
(RAC.) = - Group of proteins Backward Type I obs. mRNA (RHO.) and obs. cell migration
(TGFB.) = + Forward Type III obs. mRNA TGFB
(TNF.) = + Forward Type III obs. mRNA TGFB
RB1_p = - Phosphorylated
protein
Forward Type II pred. PRKCB1
CDC2 = - Forward Type II pred. (((CCNA.)_p):CDC2), pred. (CCNB1
p:CDC2)
ECM1 = + Forward Type III obs. mRNA ECM1
ECM2 = + Forward Type III obs. mRNA ECM2
FASLG = + Forward Type III obs. mRNA FASLG
IER3 = + Forward Type III obs. mRNA IER3
IGF1 = + Backward Type I obs. mRNA ACT1
IGF2 = - Backward Type II obs. mRNA CDKN1C, pred. TP73
IGFBP3 = - Proteins Backward Type I pred. IGF1, obs. mRNA IGF1
JUN = + Backward Type III obs. mRNA FASLG
MYCBP = - Forward Type III obs. mRNA MYCBP
PRKCB1 = - Forward Type III obs. mRNA PRKCB1
RASA1 = + Forward Type III obs. mRNA RASA1
SKP2 = + Forward Type III obs. mRNA SKP2
TGFBR2 = + Forward Type II pred. mRNA TGFBR2
TNFAIP3 = + Forward Type III obs. mRNA TNFAIP3
TP73 = - Backward Type II obs. mRNA PDGFRB
mRNA and protein complex nodes
mRNA_BCL2 = + Forward - pred. IGFBP3
mRNA_IGF2 = - mRNAs Backward - pred. IGF2, pred. IGFBP3
mRNA_TGFBR2 = + Forward - obs. EWS-FLI1
mRNA_TP53 = - Forward - pred. JUN
((CCNA.):CDK2) =
-
Backward - obs. cell-cycle G2
((CCNA.)_p:CDC2)
= -
Forward - obs. cell-cyle M
((CCNA.)_p:CDK2)
= -
Protein complexes Forward - obs. cell-cycle M
(CCNB1:CDC2) = - Backward - obs. cell-cycle M
(CCNB1_p:CDC2) =
-
Forward - obs. cell-clycle anaphase
List of predictions deduced from EWS-FLI1 regulatory network. ‘Deduction’ corresponds to the direction of propagation of the regulation in the network. The first
part of the table corresponds to functional predictions about proteins. The ‘Functional type’ column shows the result of the post-processing classification of these
predictions detailed in the Method section. The second part of the table gathers relevant predictions about other nodes in the network, that is mRNA and
protein-complexes. Although they do allow discussing the dogma of a correlation between mRNA and protein levels, such predictions are used in the Results
section to discuss the relevance of predictions about proteins. For each prediction we indicate the source of prediction, which is the minimal set of nodes
(observed or predicted) that is needed for the deduction of the prediction. For instance, the first line reads as follows: the prediction about (PIK3C.) protein node
is a forward deduction from three sources: the observation on (PIK3C.) mRNA and the predictions about (.RAS) and IGF1 nodes.
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Figure 4 Representation of predictions in the network. This figure shows parts of the network where the predictions considered in the
section ‘Discussion’ are located. It helps backtracking the source of each prediction. Part A. Predictions on TGFBR2 mRNA and protein are
deduced from the observation on EWS-FLI1. The prediction about BCL2 mRNA is deduced from the prediction about IGFBP3, deduced from the
prediction about the IGF1 protein which, in turn, is deduced from the observation on AKT1 mRNA. The prediction about the TP73 protein is
deduced from the observation on PDGFRB mRNA and serves, together with the observation on CDKN1C mRNA, as a source of the prediction
about the IGF2 protein and subsequently - about IGF2 mRNA. The prediction about the family of proteins (.RAS) is deduced from the prediction
about the IGFBP3 protein and, together with the prediction about the IGF1 protein, is a source of the prediction on family of proteins (PIK3C.).
Part B. Prediction about the JUN protein is deduced from the observation on JUN mRNA and serves as a source for the prediction about the
TP53 mRNA. Prediction about the FASLG is a forward deduction from the observation on the FASLG mRNA. Part C. Prediction about the (RAC.)
family of proteins is deduced as the only possible explanation of the combination of observations on (RHO.) mRNA family and the phenotypic
node [Cell Migration]. Part D. Prediction on phosphorylation of RB1 is a forward deduction from the prediction on PRKCB1 which is deduced
from the observation on PRKCB1 mRNA. Part E. The prediction about the CDC2 protein is a result of the correlated interactions of its precursors,
predictions on complexes ((CCNA.)^ p:CDC2)) and (CCNB1^ p:CDC2).
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up-regulated (Figure 4A). This backward deduction sug-
gests that one of the incoming regulations of TP73 pro-
tein (activations by TP73 mRNA, MAPK1 and EP300
and inhibitions by MDM2 and MYC, not shown) may
be activated by the inhibition of the fusion oncogene.
This prediction about TP73 is of great importance since
it will result in a new prediction about IGF2 and its
mRNA and will finally allow us to propose network
refinements.
Type I predictions
Our post-processing of BioQuali output pointed out
three Type I predictions, which directly indicate active
post-translational regulations in the network. These are
predictions about IGF1, IGFBP3 and the (RAC.) family
of proteins which includes RAC1, RAC2 and RAC3.
(RAC.) case study
The prediction about (RAC) node results from a path of
reasoning in several steps. We refer to Figure 4C for
details. The prediction is a backward deduction from
the observation on the phenotypic node [Cell Migration]
([cell migration] = ‘-’). This phenotypic node has two
precursors: (RAC.) and (RHO.). Notice that (RHO.) also
has two precursors: its mRNA (observed as “+”) and the
node (RAC.). According to the logic of BioQuali, the
observed variation of [Cell Migration] must be explained
by one of the incoming regulations, which means that
one of the two precursors must have a variation ‘-’.
(RAC.) being set as ‘+’ would imply that (RHO.) receives
two positive influences, which would finally imply that
[Cell Migration] is positive, contradicting the
Figure 5 RT-QPCR data on FASLG, IGF2 and EWS-FLI1 time series. Quantification of FASLG, IGF2 and EWS-FLI1 was performed by RT-QPCR
in a time series experiment. EWS-FLI1 was silenced upon shRNA induction by addition of doxycycline in the media for up to 24 days. For the
recovery series, doxycycline was omitted from the media after the 10th day of culture (dashed lines).
Figure 6 Western blotting on IGF2 and FASLG. Western blotting
of FASLG, IGF2 and beta-actin in a time series experiment. EWS-FLI1
was silenced upon shRNA induction by addition of doxycyclin in
the media for up to 17 days.
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observation on this node. This makes the original
hypothesis ((RAC.) = ‘+’) impossible and therefore
(RAC.) is predicted as ‘-’.
However, the input dataset showed that the transcript
variation of the (RAC.) family is clearly positive. This
suggests that one of the post-translational regulations
on (RAC.) protein (in our network they come from
SOS2 protein and (PIK3R.) family) is active and reverses
the effect of the production of RAC transcripts.
IGF1 and IGFBP3 case study
The predictions about IGF1 and IGFBP3 will be dis-
cussed together since they are deeply connected.
The prediction about the IGF1 node is a backward
deduction from the observation on AKT1 mRNA (Fig-
ure 4A). The increase of IGF1 protein is the only possi-
ble explanation of its target - AKT1 mRNA - up-
regulation. The IGF1 node is the target of two incoming
regulations: from its transcript and from IGFBP3 pro-
tein. However, the transcript is observed as significantly
decreasing in the Affymetrix chip. This suggests that the
predicted behavior of IGF1 protein can only be
explained by the inhibition issued in the IGFBP3 pro-
tein. The effect of IGFBP3 competes with the protein
production from its transcripts and eventually reverses
it.
The predicted variation on IGFBP3 protein is also of
the backward type. It is a direct consequence of the var-
iation of IGF1 protein: since IGFBP3 is the only inhibi-
tor of IGF1, and since IGF1 must increase from the
previous analysis, we deduce that IGFBP3 protein is
decreasing during the experiment. Nonetheless, its tran-
scripts increase significantly during the experiment. This
suggests that the production of IGFPB3 results from a
competition between the translation of its transcript and
the regulation from the (RAS.) pathway. Here, the “com-
petition” is won by (RAS.).
This prediction was compared with the previously
reported data shown in Figure 6A of [28]. A discrepancy
appeared since these new data suggest that IGFBP3 pro-
tein is induced upon silencing of EWS-FLI1.
Towards a network refinement
Using predictions to propose a relevant set of additional
observations
In order to explain the discrepancy between the predic-
tion about IGFBP3 (deduced from the network topol-
ogy) and the previously reported observation about this
protein [28], a new range of experiments was designed.
We pointed out the IGF2 node in the network since it
involves a prediction of Type II being is a direct conse-
quence of several predictions discussed above.
Indeed, the prediction about IGF2 protein is a three-
step backward deduction. It is due to the combination
of observations on CDKN1C mRNA and PDGFRB
mRNA (Figure 4). The observed variation of CDKN1C
mRNA is ‘+’, and it has two incoming interactions: from
proteins TP73 and IGF2. According to BioQuali, the
observation on CDKN1C mRNA must be explained by
one of these entries. It cannot be explained by regula-
tion from the TP73 protein (prediction addressed in
details above). Therefore, the only possible explanation
of the observed variation of CDKN1C mRNA is its inhi-
bition by IGF2. In this case, the variation of the IGF2
protein must be ‘-’, as it is stated in the prediction list-
ing (see Table 2 and Additional file 5: Results of the
constraint-based analysis). Pushing the reasoning
further, the predicted variation of IGF2 protein must be
explained by one of its incoming interactions, either by
the inhibition from the IGFBP3 protein or by the activa-
tion from IGF2 mRNA (Figure 4A). According to the
prediction about IGFBP3 protein, IGF2 mRNA can be
the only explanation of predicted variation of IGF2 pro-
tein (prediction: IGF2 mRNA = ‘-’).
In other words, according to the reasoning we have
used up to now, both IGF2 and its mRNA should
decrease during the oncogene inhibition, and this beha-
vior is shown to be characteristic from the network
topology and Affymetrix observations. Both these varia-
tions were checked experimentally. RT QPCR showed
that the level of IGF2 mRNA increases during the inhi-
bition of EWS-FLI1 (Figure 5) and Western blotting
showed that IGF2 protein does not respond significantly
to the inhibition of EWS-FLI1 (Figure 6). As for obser-
vation from [28], this was in complete disagreement
with the variations deduced from the topology of the
model.
Re-performing the analysis and pointing out lacks in the
network
A new set of observations was built according to the
new data at hand: the significant variations observed in
the Affymetrix chip were complemented by two addi-
tional data: ‘IGF2_mRNA = +’ and ‘IGFBP3 = +’. The
BioQuali analysis of the network with respect to this set
of variations resulted in an inconsistent diagnosis, indi-
cating that regulations are missing over IGF1 to explain
the new set of observations. This points out the need
for further biological investigations of this pathway to
complete the picture of regulations and pathway cross-
talks in Ewing’s cancer.
This situation illustrates the utility of our approach,
which points out weak parts of the model that should
be submitted for thorough experimentation. The con-
flicts discovered also suggest those parts of the network
model (a priori generic) which should be adapted to the
specificities of the cell line and phenotype. In this case,
our theoretical investigations of the EWS-FLI1 regula-
tory network suggest that the IGF pathway could be an
important factor in the development of Ewing’s cancer.
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This agrees with previously reported Identification of
IGF1 and IGFBP3 as EWS-FLI1 target genes in [28-31].
Conclusion
We have used a network representation to model the
behavior of genes controlled by an oncogene in the con-
text of Ewing’s sarcoma. The network gathers “gold
standard” but generic information on pathways involved
in cell proliferation and apoptosis, which are putatively
under the influence of the oncogene. The network has
been modified to include post-translational interactions
and to contain both mRNA and protein nodes. The ana-
lysis allowed us to pinpoint active interactions specific
to this cancer. We have also identified those parts of the
network which were incomplete and should be sub-
mitted for further investigation.
The analysis was performed using the open-source
software tool BioQuali and consisted of an automatic
constraint-based analysis mimicking biologist’s local rea-
soning on a large scale. The logical constraints used by
the tool were proved to be relevant for our experimental
setting - steady state shifts - in a previous mathematical
work [24].
The results from the tool were post-processed by (1)
differentiating between transcriptional and post-transla-
tional products of gene expression (2) analyzing the pre-
dicted variations to localize potentially active regulations
and suggest network corrections. The underlying idea
behind this process was that relevant information will
be derived from situations where the naive application
of the transcription dogma in eukaryotes could not
apply.
The originality of our regulatory network analysis lies
in the combination of prediction and localization of
inconsistencies and contradictions. Predictions enhance
the set of observable nodes by including products that
are not accessible to experiments (such as active pro-
teins in transcriptomic studies) or for which the accu-
racy of measurement is insufficient. An enhanced
network can render complementary analysis such as
sub-network classification methods and hypothesis gen-
eration more efficient. It also pinpoints active interac-
tions and reveals disease specificities. Network failures
and inconsistencies such as missing interactions or
errors in node interpretation can also be localized in
our approach. Corrections and further experiments are
proposed in this case.
Last but not least, this type of analysis is iterative. As
with any predictive method in systems biology, the
results of the consistency checking depend on both the
network and experimental data at hand: an inconsis-
tency diagnosis locates lacunae in the model with
respect to available data; predictions are direct
consequences of those available data. Therefore, switch-
ing to another dataset may considerably modify the set
of predictions and even change the result of the consis-
tency checking if the network topology fails to explain
the new set of inputs. Concretely, predictions in a first
step can become inconsistencies when confronted with
new data and require network correction in further
steps. This happened in present work: applying the
method to Ewing’s sarcoma network and data we sug-
gest that the full dataset explains a few post-transla-
tional processes. The post-processing of the results of
the analysis led to proposition of the complementary
experiments. These complementary experiments vali-
dated some of the predictions but also revealed lacks in
the generic network. We have confirmed the specific
role of IGF in the development of Ewing’s cancer and
have localized parts of this pathway that should be stu-
died as a priority in the future.
More generally, it is crucial to build networks in a
manner that realistically takes into account various
sources of expression variation (transcription factors
activities, alternative splicing, post-translational modifi-
cations of proteins, etc.). Thus, other elements shall be
considered in a network structure, and extensions are in
progress. These may be microRNAs, mRNAs, proteins,
phosphorylated proteins, etc. depending on the type of
the experimental data available to the modeler. For
instance, our formalism can easily integrate the effect of
genetic amplifications by introducing DNA node type
whose attribute is the gene copy number variation
(work in progress). Alternative splicing is simply a ques-
tion of multiplying the proteins nodes resulting from a
given mRNA. Our approach is a first step forward in
this direction.
Additional material
Additional file 1: Interaction graph adapted from original network.
The non-modified interaction graph (no differentiation between mRNAs
and proteins done) is shown in the file ‘Additional file 1.csv’, which is
structured to be readable by the BioQuali tool.
Additional file 2: Modified interaction graph. ‘Additional file 2.cvs’
contains the network which includes all modifications as described in
the text of the paper. It is also in a BioQuali-readable format of
interaction network representation.
Additional file 3: Results of statistical analysis of microarray data
[21]. ‘Additional file 3.xls’ comprises calculated slopes, variations and
corresponding p-values for microarray data of gene responses on both
inhibition and recovery of EWS-FLI1. All the transcript variants of genes
present in our network model were grouped and the statistical tests
were applied to such ‘gene’ data rather than ‘transcript variant’ data, to
give a comprehensive picture of gene behaviors.
Additional file 4: Set of experimental observations. ‘Additional file 4.
csv’ file presents the observation dataset resulting from the statistical
analysis of microarray data shown in Additional file 3.
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Additional file 5: Results of the constraint-based analysis. ‘Additional
file 5.xls’ contains the results of constraint-based modeling of the
extended EWS-FLI1 regulatory network with the integrated experimental
observations set. The first column shows the discovered inconsistencies
(while analyzing the original interaction network). The following columns
display the consistency of the modified network (mRNA nodes included)
with the dataset and predictions obtained after the analysis.
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